Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026
Same author

Detection of Gene Fusions in Soft Tissue Sarcoma Using Next-Generation Sequencing.

Genes·2026
Same author

Chronic radiation-induced dermatitis: what is new in 2024? A narrative review.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology·2026
Same author

Long-term efficacy of radical treatment of patients with clear cell sarcoma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism-A Review.

Cancers·2026

Related Experiment Video

Updated: Jan 6, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.6K

Dermatofibrosarcoma Protuberans (DFSP): Diagnostics and Molecular Pathology.

Piotr Remiszewski1,2, Joanna Taczała1,2, Marcin Rosiński1,2

  • 1Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska- Curie National Research Institute of Oncology, Warsaw, Poland.

Current Treatment Options in Oncology
|October 1, 2025
PubMed
Summary

Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. Accurate diagnosis and surgical removal are crucial due to its local aggressiveness and recurrence risk, with novel staging integrating fibrosarcoma variant features.

Keywords:
COL1A1-PDGFB gene fusionDermatofibrosarcoma protuberansDifferential diagnosisFibrosarcomatous transformationImatinib mesylate therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.5K

Related Experiment Videos

Last Updated: Jan 6, 2026

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
10:16

Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines

Published on: October 8, 2015

13.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.5K

Area of Science:

  • Dermatopathology
  • Oncology
  • Molecular Biology

Background:

  • Dermatofibrosarcoma protuberans (DFSP) is a rare, low-grade cutaneous mesenchymal neoplasm.
  • DFSP often presents as a slow-growing plaque or nodule, frequently misdiagnosed as benign conditions.
  • Local aggressiveness, subclinical spread, and recurrence necessitate precise diagnosis and complete surgical excision.

Purpose of the Study:

  • To review diagnostic modalities for DFSP, including histopathology, immunohistochemistry, and imaging.
  • To elucidate the molecular underpinnings of DFSP, focusing on genetic drivers and signaling pathways.
  • To propose a novel staging system for DFSP that incorporates fibrosarcoma (FS) differentiation.

Main Methods:

  • Review of histopathology and immunohistochemistry (CD34, factor XIIIa, S100, PRAME).
  • Assessment of clinical presentation and imaging techniques (ultrasound, MRI, PET/CT).
  • Analysis of molecular diagnostics, including COL1A1-PDGFB fusion detection (FISH, RT-PCR) and other genetic alterations.

Main Results:

  • The COL1A1-PDGFB fusion is a pathognomonic marker for DFSP, driving PDGFRβ activation and serving as a therapeutic target (imatinib).
  • Additional genetic alterations (e.g., COL1A2-PDGFB, FBN1-CSAD fusions, CDKN2A/B deletions) are associated with the aggressive fibrosarcomatous variant.
  • Established diagnostic markers and imaging modalities are critical for accurate assessment.

Conclusions:

  • Accurate diagnosis of DFSP relies on a combination of clinical, histopathological, immunohistochemical, and molecular findings.
  • Understanding the molecular basis, including genetic drivers and signaling pathways (Ras-MAPK, PI3K-Akt, FGFR), is key to DFSP management.
  • A proposed novel staging system integrating fibrosarcoma differentiation aims to improve risk stratification for DFSP.